We are monitoring the impact of COVID-19 on APAC Uterine Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1413
Share on
Share on

Asia Pacific Uterine Cancer Therapeutics Market Research Report – Segmented By Type, Therapy, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1413
Pages: 135

APAC Uterine Cancer Therapeutics Market Size (2021 to 2026)

The size of the Uterine Cancer Therapeutics Market in the Asia Pacific is expected to reach USD 4.42 Billion by 2026 from USD 3.20 Billion in 2021, growing at a CAGR of 6.67% during the forecast period 2021 to 2026.

Uterine cancer is one of the most commonly prevailing malignant tumors that start in the uterus cells and spread to other parts of the body. Uterine cancer is mainly of two types such as uterine sarcoma and endometrial carcinoma. As a result, more therapies have evolved to manage uterine cancer types, including surgery, chemotherapy, radiation therapy, immunotherapy, and hormone therapy.

Increasing focus of government to provide early detection programs for uterine cancer, rising provision of optimal therapeutic strategies to treat uterine cancer, growing economy, and increasing advancements in the cancer screening & treatment methods are driving the growth of the Asia-Pacific Uterine Cancer Therapeutics Market.

However, the high cost of the treatment solutions, limited access to advanced cancer therapies in some developing regions are expected to restrain the growth of the Uterine Cancer Therapeutics Market.

This research report on the APAC Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:

By Type:

  • Uterine Sarcoma
  • Endometrial Carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Others

By Therapy:

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormone Therapy

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia Pacific uterine cancer therapeutics market is one of the fastest-growing regions globally. Therefore, the APAC Uterine cancer therapeutics market is expected to grow at a significant CAGR during the forecast period. The regional market growth is attributed to the improving healthcare infrastructure, rising healthcare spending, and increasing knowledge of uterine disorders and accessible therapeutics. In addition, subsequent technology developments, drug development innovation, and favorable government policies are the primary factors driving the market growth. In addition, following research into the disease’s vital nature and impact, healthcare providers and governments in the Asia Pacific region are launching awareness campaigns in several areas.

In APAC, the Indian uterine cancer therapeutics market is expected to register a promising CAGR during the forecast period. India has a National Cancer Control Program established back then; it has contributed to the growth of Regional Cancer Centers (RCCs), oncology departments in medical institutes, and financial assistance for the procurement of teletherapy machines. Furthermore, cancer awareness initiatives are being held to educate women about the seriousness of uterine cancer. The risk of uterine cancer is higher in women over the age of 50. It has also been revealed that cervical cancer is more common in developing countries such as India and China, accounting for 80 percent of all cases.

The Chinese uterine cancer therapeutics market is anticipated to account for a promising share in the APAC market during the forecast period. Technological advancements in the healthcare sector, favorable reimbursement policies, and availability of advanced healthcare facilities. According to the Journal of Gynecological Oncology 2020, endometrial cancer is a common gynecologic malignancy in Japan, with the highest prevalence among individuals with gynecologic malignant tumors. In 2017, the age-adjusted death rate for endometrial cancer in Japan was 2.0.

The Australian uterine cancer therapeutics market is forecasted to be growing at a prominent CAGR from 2021 to 2026. According to Cancer Australia in 2019. As a result of the above causes, the segment is predicted to develop in the following years. Uterine cancer claimed the lives of 527 people in Australia, according to Cancer Australia. In 2019, it was estimated that 562 people died. Furthermore, according to the research, a female's probability of dying from uterine cancer is 1 in 205. Moreover, governments in several Asia Pacific regions are promoting public awareness campaigns. As a result, the market is expected to grow fast over the forecast period, owing to the government’s and healthcare providers’ increased focus.

KEY MARKET PLAYERS:

A few of the notable companies operating in the APAC uterine cancer therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.

1.Introduction             

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods      

                1.4 General Study Assumptions                

2. Research Methodology 

                2.1 Introduction         

                2.2 Research Phases 

           2.2.1 Secondary Research            

           2.2.2 Primary Research 

           2.2.3 Econometric Modelling     

           2.2.4 Expert Validation  

                2.3 Analysis Design    

                2.4 Study Timeline     

3. Overview                 

                3.1 Executive Summary                

                3.2 Key Inferences    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                 

                4.1 Market Drivers     

                4.2 Market Restraints                    

                4.3 Key Challenges    

                4.4 Current Opportunities in the Market               

5. Market Segmentation                         

                5.1 By Type   

           5.1.1 Endometrial Carcinoma     

      5.1.2.1 Adenocarcinoma

      5.1.2.2 Carcinosarcoma

      5.1.2.3 Squamous cell carcinoma

      5.1.2.4 Others

           5.1.2 Uterine Sarcoma  

                5.2 By Therapy                 

           5.2.1 Surgery    

           5.2.2 Chemotherapy     

           5.2.3 Radiation Therapy

           5.2.4 Immunotherapy   

           5.2.5 Hormone Therapy

6. Geographical Analysis    

                6.1 Introduction         

                6.2 China       

                6.3 India         

                6.4 Japan       

                6.5 South Korea               

                6.6 Australia 

7. Pipeline Product Analysis                   

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline

                7.4 Clinical Trials         

           7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

           7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

           7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                   

                8.1 PESTLE analysis    

           8.1.1 Political     

           8.1.2 Economic 

           8.1.3 Social         

           8.1.4 Technological         

           8.1.5 Legal          

           8.1.6 Environmental      

                8.2 Porter’s Five analysis         

           8.2.1 Bargaining Power of Suppliers        

           8.2.2 Bargaining Power of Consumers    

           8.2.3 Threat of New Entrants     

           8.2.4 Threat of Substitute Products and Services

           8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis

                9.1 Abbott Laboratories (U.S.)                   

           9.1.1 Overview

           9.1.2 Product Analysis   

           9.1.3 Financial analysis  

           9.1.4 Recent Developments       

           9.1.5 SWOT analysis       

           9.1.6 Analyst View          

                9.2 Ariad Pharmaceuticals, Inc. (U.S.)

                9.3 Becton, Dickinson and Company (U.S.)      

                9.4 F. Hoffmann-La Roche AG (Switzerland)   

                9.5 GlaxoSmithKline Plc (U.K.)                   

                9.6 Merck & Co., Inc. (U.S.)    

                9.7 Novartis AG (Switzerland)                    

                9.8 Sanofi (France)    

                9.9 Siemens Healthcare GmbH (Germany)      

                9.10 Takeda Pharmaceutical Company Ltd. (Japan)     

10.Competitive Landscape

                10.1 Market share analysis     

                10.2 Merger and Acquisition Analysis

                10.3 Agreements, collaborations and Joint Ventures  

                10.4 New Product Launches  

11.Market Outlook & Investment Opportunities          

Appendix 

                a) List of Tables                

                b) List of Figures         

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Uterine Cancer Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Endometrial Carcinoma Market By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Uterine Sarcoma Market By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Uterine Cancer Surgery Market By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Uterine Cancer Chemotherapy Market By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Uterine Cancer Immunotherapy Market By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Uterine Cancer Radiation Therapy Market By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Uterine Cancer Hormone Therapy Market By Region, From 2021 to 2026 (USD Billion)
  11. China Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  12. China Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  13. India Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  14. India Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  15. Japan Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  16. Japan Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  17. South Korea Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  18. South Korea Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  19. Australia Uterine Cancer Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  20. Australia Uterine Cancer Therapeutics Market By Therapy, From 2021 to 2026 (USD Billion)
  21. Asia-Pacific Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Adenocarcinoma Market By Region, From 2021 to 2026 (USD Billion)
  23. Asia-Pacific Carcinosarcoma Market By Region, From 2021 to 2026 (USD Billion)
  24. Asia-Pacific Squamous cell carcinoma Market By Region, From 2021 to 2026 (USD Billion)
  25. Asia-Pacific Other Endometrial Carcinoma Market By Region, From 2021 to 2026 (USD Billion)
  26. China Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)
  27. India Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)
  28. Japan Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)
  29. South Korea Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)
  30. Australia Endometrial Carcinoma Market By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample